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Abstract
Background: Bitter Melon (BM) has been used as a functional food in traditional Chinese and Indian medicine for
many generations and has gained a great deal of attention due to its apparent benefits in moderating some of the
pathogenic processes in a variety of inflammatory conditions. BM extract (BME) has been shown to possess strong
anti-oxidant properties. In addition, it can ameliorate oxidative stress and potentially ER stress. There is increasing
evidence that oxidative and ER stress are major contributors for intestinal secretory cell dysfunction which leads to
local inflammation and disease pathogenesis that are hallmarks of inflammatory bowel diseases (IBD). Hence, the
search for potential therapeutics against ER stress and oxidative stress in intestinal epithelial secretory cells may
provide valuable resources for the management of IBD. The aim of the present study was to investigate the effects
of BME in ameliorating ER stress in colonic epithelial cells.
Methods: Human colonic adenocarcinoma LS174T cells were used for the assessment of BME effects on colonic
epithelial cells in vitro. Cell viability was assessed using trypan blue exclusion and the effect of BME in ameliorating
tunicamycin (TM)-induced ER stress was determined by analysing the mRNA expression of the common ER stress
markers; ATF6, XBP1, GRP78, CHOP and PERK by quantitative RT-PCR and GRP78 and CHOP by western blot.
Results: In the absence of ER stress, BME exhibited no cell toxicity up to 2.0% w/v and no significant effect on the
basal mRNA expression of ER stress markers in LS174T cells. In contrast, pre-treatment of LS174T cells with BME
followed by induction of ER stress resulted in a significant decrease in mRNA expression of ATF6, XBP1, GRP78,
CHOP and PERK and protein expression of GRP78 and CHOP. Co-treatment during induction of ER stress and post-
treatment following induction of ER Stress in LS174T cells resulted in a lower but still significant reduction in mRNA
expression levels of most ER stress markers.
Conclusions: This is one of the first studies demonstrating the efficacy of BME in reducing expression of ER stress
markers in colonic epithelial cells suggesting the potential of BME as a dietary intervention in ameliorating ER stress
and oxidation in IBD. Interestingly, while the most significant effect was seen with pre-treatment of cells with BME
there was a reduced but still significant effect when co-treated or even post-treated. This suggests that BME may
even be effective in modulating ER stress in the face of an existing cell stress environment.
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Background
Bitter melon (BM; Momordica charantia), also known as
bitter gourd, karela or balsam pear, belongs to the Cucurbi-
taceae family and is widely cultivated in tropical regions
including Asia, Africa and South America. It has been used
in traditional Chinese and Indian medicines for gastro-
intestinal disorders as well as diabetes and its complica-
tions [1–4]. Extensive characterization of BM (for review
see [5]) has identified various bioactive components of BM
such as kuguacin J, karaviloside XI, kuguaglycoside C,
momordicoside Q-U, charantin, vicine, polypeptides and a
variety of polyphenols and proteins that are thought to
contribute to its beneficial effects [3, 5–7]. BM has gained
worldwide attention due to its apparent diverse physio-
logical benefits such as hypolipidaemia, hypoglycaemia,
anti-viral, anti-inflammatory, anti-cancer properties as well
as strong antioxidant properties [7–12]. However, little is
known about the effects of BM on ER-stress related inflam-
matory conditions and its potential benefits in these condi-
tions. Inflammatory bowel disease (IBD) is characterised by
a chronic and exaggerated inflammatory immune response
to the intestinal microbial flora influenced by a complex
interaction of genetic predisposition, environmental trig-
gers and dysregulated immune system, which comprise
primarily Crohn’s disease (CD) and ulcerative colitis (UC)
[13, 14]. Intestinal barrier dysfunction due to defects in the
intestinal secretory cells as a result of increased oxidative
and ER stress has been recognised as a major contributor
to the pathogenesis of IBD [13, 15].
Several mouse models such as Winnie, Eeyore and
Kenny (missense mutations in MUC2) and Agr2 defi-
ciency (loss of MUC2 production) illustrate the link be-
tween intestinal epithelial cell ER stress with intestinal
inflammation [13, 16]. Elevated levels of oxidative stress
in intestinal secretory cells as a consequence of ER stress
leads to the depletion of intestinal mucins, enhanced
mucosal permeability and extensive disruption of the
intestinal epithelial cells and results in spontaneous
intestinal inflammation [17, 18]. We used LS174T
colonic epithelial cells as they have the highest expres-
sion of MUC2 mucin, the major mucin that fills human
colonic lumen and hence a better representation of co-
lonic goblet cells that have the propensity for ER stress.
Several mechanisms have been proposed to explain
the connection between ER stress and oxidative stress
[19]. The formation of intra and inter-molecular disul-
phide bonds through oxidation involving two major
enzymes, protein disulphide isomerase (PDI) and ER
oxidoreductin 1 (ERO1) are fundamental to the protein
folding process. This process requires significant energy
through oxidation of cysteine residues and electron
transfer. An excess protein-folding load can result in the
accumulation of ROS triggering a cellular inflammatory
response. Increased consumption of glutathione (GSH)
to repair the unfolded or mis-folded proteins reduces
available cellular GSH in the cells, leading to the initi-
ation of the unfolded protein response (UPR), which is a
signature of ER stress [20].
With a developing understanding of the pathogenesis
of IBD, various therapeutic strategies that ameliorate ER
stress and oxidative stress in IBD have been introduced.
Examples include, Infliximab; a mAb targeting tumour
necrosis factor (TNF) to suppress TNF-mediated inflam-
matory cytokine release, Salubrinal, an eIF2-α dephos-
phorylation inhibitor protecting cells from ER stress
induced apoptosis, and more recently, Dexamethasone
(DEX); suppressing ER stress and UPR activation in both
in vitro and in vivo studies [13, 21–23].
Furthermore, the potential of antioxidant therapeutic
drugs such as sulfasalazine, immunosuppressive agents,
steroids, iron chelators and N-acetylcysteine (NAC) have
been shown to be beneficial in IBD patients [17, 24]. How-
ever, as a result of the high health-care costs and the pres-
ence of drug side effects, there is increased attention
towards the use of functional foods as a possible thera-
peutic approach for treating, or even potentially minimis-
ing the risk of developing IBD [3, 25, 26]. Although
numerous studies have shown the extensive beneficial
effects of BM in a variety of conditions, little is known
regarding the effect of BM towards ameliorating ER
stress and oxidative stress in colonic epithelial cells.
The aim of this study was to investigate the potential
of BM extract (BME) to ameliorate TM-induced ER
stress in colonic epithelial cells.
Methods
Preparation of BME by pressurised hot water extraction
Active ingredients were extracted from BM (Chinese var-
iety; sourced from local vegetable super market in Hobart,
Tasmania, Australia labelled as bitter melon) by pres-
surised hot water using a modification of a method previ-
ously described for natural product isolation [27, 28].
Fresh whole BM was sliced and dried in an oven at
35 °C until brittle. The slices were ground to a coarse
powder and 4 g of this preparation was mixed with 12 g
of acid washed sand followed by packing into the filter
basket of a household espresso coffee machine.
Approximately 200 mL of deionised water was passed
through the sample and the extract was evaporated to dry-
ness by rotary evaporation under vacuum at 50 °C. Typical
yields were 1 g BME per 4 g dehydrated BM. Working
BME used for the in vitro studies was prepared by dissolv-
ing 1.0 g of dried BME in 50 mL of MilliQ grade water
with periodic vortexing over 15 min. The extract was
centrifuged at 560 × g at 4 °C for 30 min to remove solids
providing a BME of 20% (w/v) which was stored at −20 °C
for later use. Stock BME was diluted to the desired con-
centration in PBS for subsequent experiments.
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LC-MS Analysis of BME
Aqueous samples of BME prepared above were analysed
using a Waters Acquity H-Class UPLC instrument coupled
to a Waters Xevo triple quadrupole mass spectrometer. A
Waters Acquity UPLC BEH C18 column (2.1 mm×
100 mm× 1.7 μm) was used. The mobile phase consisted of
two solvents: 10 mM Ammonium Formate in water (solv-
ent A) and Acetonitrile (solvent B). The UPLC program
was initially 100% A, followed by a linear gradient to 30% A
at 4.0 min and 10% A at 6 min, which was held for 2 min
before returning to initial conditions and re-equilibration
for 3 min. The flow rate was 0.35 mL/min, the column was
held at 35 °C, and the sample compartment was at 6 °C.
The mass spectrometer was operated in positive ion elec-
trospray mode with a needle voltage of 2.6 kV, a desolvation
gas (Nitrogen) flow of 950 L/hr at 450 °C and cone gas flow
of 50 L/hr. Full scan mass spectrometry experiment was
conducted over the range (m/z) 150 to 1150 with a cone
voltage of 32 V and scan time of 0.5 sec.
Antioxidant activity of BME
The anti-oxidant activity of BME was assessed by its
effect on the copper-induced oxidation of human serum.
Fasting plasma was collected from 6 healthy individuals
(three men and three women) and isolated serum was
frozen at −80 °C prior to analysis of BME serum oxida-
tion. Copper-induced oxidation of human serum was
performed in duplicate using the method described pre-
viously [29, 30]. Serum was diluted 50-fold in phosphate
buffered saline (pH 7.4), incubated with increasing con-
centrations of BME (0, 0.0625, 0.125, 0.25, 0.50 and
0.75%), and subjected to copper (50 μM)-induced oxida-
tion. Oxidation kinetics were determined for each serum
sample and concentrations of BME by using a multiposi-
tion spectrophotometer (Cintra 10E UV–vis, GBC Scien-
tific Equipment, AUS) to measure the absorbance at
245 nm at 37 °C for every 10 min for 360 min.
LS174T cell culture
Human colon carcinoma cells LS174T (ATCC) were cul-
tured as an adherent monolayer in RPMI-1640 + Gluta-
max (Life Technologies, AUS), supplemented with 10%
heat-inactivated FBS (Gibco BRL, AUS) and penicillin
(1000 U/mL) and streptomycin (1000 ug/L) (Gibco BRL,
AUS). Cultures were maintained at 37oC in a humidified
5% CO2 and media replaced and cells passaged every 2
to 4 days. For experimental procedures, cultures were
grown to 80-95% confluence and harvested using 0.25%
TrypLe Express (Life Technologies, AUS). Cells were
washed twice in culture media and number and viability
were assessed using the Countess® cell counter (Life Tech-
nologies, AUS) according to manufacturer’s instructions.
Effect of BME on cell viability
To assess the effect of BME on cell viability of LS174T
cells, 12-well cell culture plates (Greiner, AUS) were
seeded at a density of 3.0 × 105 cells per well in 2.0 mL
of medium and incubated overnight at 37oC/5% CO2 to
allow the cells to adhere. The medium was replaced the
next day with medium containing BME (0.5, 1.0, 1.5 and
2.0% w/v). After 6 h incubation, the cells were washed
with HBSS and harvested by detaching the cells from
the growth surface with TrypLe Express (Life Technolo-
gies, AUS), washed twice with HBSS and cell viability
assessed using the Countess® cell counter (Life Tech-
nologies, AUS) according to manufacturer’s instructions.
Baseline expression of ER markers in LS174T cells treated
with BME
To assess the baseline expression of ER stress markers
in LS174T cells treated with BME, 12-well cell culture
plates (Greiner, AUS) were seeded at a density of 3.0 ×
105 cells per well in 2.0 mL of medium and incubated
overnight at 37oC/5% CO2 to allow the cells to adhere.
The medium was replaced the next day with treatment
medium containing BME (0.001, 0.01, 0.1, 0.5 and 1.0%)
followed by incubation for 6 h at 37oC/5% CO2. Control
cells were treated with PBS as vehicle controls. Total
RNA was extracted and mRNA expression of ER stress
markers assessed as described below.
Effect of BME on the expression of ER stress markers in
LS174T in response to induction of ER stress with TM
The effect of BME on TM-induced ER stress in LS174T
cells was assessed in a pre, during and post treatment regi-
men. For mRNA expression analysis, 12-well cell culture
plates were seeded at a density of 3.0 × 105 cells per well in
2.0 mL of medium and incubated overnight at 37oC/5%
CO2 to allow the cells to adhere. For protein expression
analysis, 30 mm cell-culture dishes (Greiner, AUS) were
seeded with 1 × 106 of in 5.0 mL of medium and incubated
overnight at 37oC/5% CO2 to allow the cells to adhere. For
the pre-treatment regimen, the media was replaced the next
day with medium containing BME (0, 0.125% and 0.25%)
for 6 h at 37oC/5% CO2 after which media was replaced
with fresh medium containing TM (10 μg/mL in DMSO)
for a further 6 h at 37oC/5% CO2. For the co-treatment
regimen, the media was replaced with medium containing
BME (0, 0.125% and 0.25%) and TM (10 μg/mL in DMSO)
for 6 h at 37oC/5% CO2. For the post-treatment regimen,
the media was replaced with medium containing TM
(10 μg/mL in DMSO) for 6 h at 37oC/5% CO2 after which
media was replaced with fresh medium containing BME (0,
0.125% and 0.25%) for a further 6 h at 37oC/5% CO2. Con-
trol cells were treated with DMSO as a vehicle control at
time points described. Total RNA and total protein was
extracted and mRNA or protein expressions of ER stress
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markers were assessed as described below. Each treatment
was performed in duplicate and the data presented are the
mean ± SEM of 5 independent experiments.
RNA extraction and cDNA synthesis
Total RNA was extracted from 3 × 105 treated LS174T
cells using RNeasy Mini Kit (Qiagen, AUS) following the
manufacturer’s protocol including an on-column DNase
digestion using the RNase-Free DNase set (Qiagen, AUS)
to remove gDNA. RNA quality and quantity was assessed
using the Experion automated electrophoresis system
(Bio-Rad Laboratories, AUS) and RNA samples with an
RQI > 7.0 were considered suitable for expression analysis.
One microgram of total RNA was reverse transcribed to
cDNA using the iScript cDNA synthesis kit (Bio-Rad
Laboratories, AUS) following the manufacturer’s protocol.
Quantitative real time polymerase chain reaction (qRT-PCR)
Quantitative RT-PCR was performed using predesigned
Taqman® probe/primer assays (Life Technologies, AUS)
for GAPDH (Hs03929097_gl), ATF6 (Hs00232586_m1),
XBP1 (Hs00231936_m1), GRP78 (Hs0060719_gH), CHOP
(Hs00358796_g1) and PERK (Hs00984006_m1). The qRT-
PCR reactions contained 40 ng cDNA, TaqMan Fast
Advanced Master Mix (Life Technologies, AUS), 1 μL of
gene specific Taqman probe/primer mix in a total volume
of 20 μL. Reactions were performed in duplicate on the
StepOne Plus RT-PCR system (Life Technologies, AUS)
with thermal cycling conditions of: an initial denaturation
step at 95 °C for 20 s, followed by 40 cycles at 95 °C
for 1 s and 60 °C for 20 s. The mean threshold cycle
was determined for each sample and used for relative
expression analysis.
Western blot analysis of GRP78 and CHOP
Total cell protein was extracted from 1 × 106 treated
LS174T cells by firstly washing the cells with HBSS
followed by homogenization in 2 mL of RIPA buffer/
10% of Protease Inhibitor (Sigma-Aldrich, AUS) and
then cleared by centrifugation at 12000 rpm for 20 min
at 4 °C. Thirty micrograms of protein from each sample
was denatured in Laemmli loading buffer (Bio-Rad
Laboratories, AUS) and separated on precast 12% SDS-
PAGE gels (Bio-Rad Laboratories, AUS) followed by
overnight transfer onto PVDF membranes (Millipore,
AUS) at 30 mV at 4 °C. The blot was blocked with 5%
non-fat milk, before being incubated with anti-GADPH
(#14C10, 1:3000, Novus Biologicals, AUS), anti-GRP78
(NBP-06274, 1:1000, Novus Biologicals, AUS) and anti-
CHOP (NBP2-13172, 1:1000, Novus Biologicals, AUS)
overnight at 4 °C in blocking buffer. The blot was
washed in PBST and incubated with appropriate species
monoclonal horseradish peroxidase-conjugated anti-IgG
secondary antibodies (1:5000) for 1 h at 20 °C. Bands
were visualized using the Supersignal West Pico chemi-
luminescent kit (Thermo Scientific, AUS), digitised and
band intensities determined using a Fuji LAS-3000
Imager (Fuji Life Sciences, JPN). Samples from all
groups were included in each individual blot to ensure
accurate quantification across multiple blots.
Data analysis
Copper-induced oxidation curves were plotted using PRISM
v5 (GraphPad Software, San Diego, CA, USA) and antioxi-
dant capacity of BME was assessed by calculating lag time,
rate of oxidation and maximum change in absorbance for
each curve. Lag time, an indicator of the protection of the
serum against oxidation, was determined as the intercept be-
tween baseline (time zero) and the tangent of the absorbance
curve during the propagation phase. The rate of oxidation
was calculated as the slope of the propagation phase. The
maximum change in absorbance was calculated by the dif-
ference between 0 min to 360 min for each BME concentra-
tion tested in each of the serum samples. The lag time and
the rate of oxidation were calculated manually by blinding
each concentration for each serum sample to avoid any bias.
Data are presented as mean ± SEM and significance
testing achieved using two-way ANOVA followed by
Games-Howell pairwise comparisons using SPSS v20.0
software (IBM, Armonk, NY, USA).
Relative mRNA expression for the ER stress markers
and significance testing to controls was conducted using
Relative Gene Expression (REST) 2009 software (Qiagen,
AUS) based on the ΔΔCt method [31] where expression
of each gene in each treatment group was expressed rela-
tive to the mean of a relevant vehicle control or treatment
group as described and normalised to the housekeeping
gene, GAPDH and significance testing achieved through a
pair-wise fixed reallocation randomisation test. Data are
presented as the mean mRNA fold change ± SEM and
significance testing achieved using two-way ANOVA
followed by Games-Howell pairwise comparisons using
SPSS v20.0 software (IBM, Armonk, NY, USA).
Relative protein expression for ER stress markers was
determined from band intensities and normalized using
GADPH expression and calculated as relative expression
over vehicle.
Data are presented as mean ± SEM and significance
testing achieved using two-way ANOVA followed by
Games-Howell pairwise comparisons using SPSS v20.0
software (IBM, Armonk, NY, USA).
Results
LC-MS analysis of BME yields a complex mix of constituents
LC-MS analysis of the bitter melon extract indicates a
complex mixture and the potential for four major com-
ponents to be present (Fig. 1a). Analysis of the mass
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Fig. 1 LC-MS analysis of steam extracted BME. a Constant Neutral Loss LC chromatogram using a Waters Acquity UPLC BEH C18 column and
gradient Formate: Acetonitrile elution profile. b MS analysis of significant LC peaks (peaks 1–6) by full scan mass spectrometry conducted over
the range (m/z) 150 to 1150 with a cone voltage of 32 V and scan time of 0.5 sec
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spectra of these peaks was unable to be assigned to me-
tabolites previously isolated, particularly the anti-
diabetic triterpenoid glycosides reported previously
(Fig. 1b) [32].
BME possesses potent antioxidant capacity
We first analysed the anti-oxidant capacity of BME by
determining its ability to ameliorate copper-induced
oxidation of serum from healthy volunteers (Additional
file 1 Figure S1). An increase in lag time of oxidation
was observed with increasing concentrations of BME
(Additional file 2 Table S1) where the lag time ranged
from 144 ± 15 min for vehicle to >360 min for BME
0.75%. The lag times for all concentrations of BME at
0.125% BME or greater were significantly longer (p <
0.05) than the control. There was no significant
change in the rate of oxidation with increasing con-
centrations of BME. The maximum change in absorb-
ance ranged from 0.570 ± 0.035 for the vehicle to
0.490 ± 0.0.038 abs at BME 0.25% (Additional file 2
Table S1) but was not significantly different, while the
maximum change in absorbance for the BME treat-
ments of 0.5% and 0.75% were significantly lower
(0.295 ± 0.045 and 0.079 ± 0.009 respectively; p < 0.05)
due to incomplete oxidation reaction resulting from
an increased lag time.
Effect of BME treatment on cell viability and activation of
UPR in LS174T cells
Increasing concentrations of BME up to 1.0% (w/v) for
6 h did not affect the viability of LS174T cells compared
to vehicle, as determined by trypan blue exclusion
(Data not shown).
The activation of UPR in LS174T cells treated with in-
creasing concentrations of BME for 6 h was assessed by
quantitative mRNA expression for ATF6, XBP1, GRP78
and CHOP.
Compared to vehicle-treated cells no significant dose-
dependent effects of BME on the mRNA expression
levels of any of the markers were detected in LS174T
cells (Fig. 2).
Effect of pre, co and post treatment using BME on
TM-induced ER stress in LS174T cells
We next investigated the efficacy of BME in ameliorating
ER stress in LS174T cells. Exposure to tunicamycin
(10 μg/mL) for 6 h resulted in a significantly increased
mRNA expression of all ER stress markers relative to ve-
hicle treated cells; ATF6 (2.62 ± 0.18 fold; 284 p < 0.05),
XBP1 (2.6 ± 0.26 fold; p < 0.05), GRP78 (13.0 ± 0.7 fold;
p < 0.01), CHOP (93.2 ± 1.28 fold; p < 0.001) and PERK
(7.12 ± 0.83; p < 0.01) (mean ± SEM; n = 5) corresponding
to ER stress induction. Pre-treatment of LS174T cells
Fig. 2 mRNA expression of UPR genes ATF6, XBP1 GRP78 and CHOP in LS174T cells treated with BME 0.001 –1.00% for 6 h were measured by
qRT-PCR and relative mRNA expression levels are vs control and normalised to GAPDH (n = 3). Data are shown as the mean fold change ± SEM
(vs vehicle: *, **, ***; p < 0.05, p < 0.01 and p < 0.001 respectively)
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with 0.125% or 0.25% BME for 6 h followed by induction
of ER stress by exposure to tunicamycin (10 ug/mL) for
a further 6 h significantly reduced the mRNA expression
of all markers at both concentrations of BME tested
(Fig. 3) indicating that BME suppresses TM-induced ER
Stress in LS174T cells. ATF6 and CHOP were sup-
pressed 3.3 and 3.1 fold respectively by pre-treatment
with 0.125% BME while PERK, XBP1 and GRP78 which
were suppressed 2.8, 1.9 and 1.9 fold respectively. Inter-
estingly, both co-treatment and post-treatment of
LS174T cells during and after TM-induced ER stress
respectively also reduced the expression of most ER-
stress markers but to a lesser extent with no significant
affect seen for ATF6 and PERK for the post-treatment
regimen (Fig. 3). Similar responses to BME were also
seen in the cellular protein levels of GRP78 and CHOP
as shown by western blot analysis (Fig. 4) confirming that
modulation of genetic expression by BME is reflected in
active protein suppression.
Discussion
In this study, we have for the first time described the
ability of BME in ameliorating ER stress in LS174T co-
lonic epithelial cells. BME appears to moderate ER stress
via a mechanism that reduces the expression of the ER
stress marker CHOP expression more than other ER
stress markers.
Detailed analysis of the constituents of BM typically
yield a complex array of potentially bioactive compounds
which have been reviewed comprehensively [5]. Our LC-
MS analysis of the steam extractable components of BM
used in this study also showed a complex mixture of
components, though six major peaks were detected.
However, mass spectra analysis of these peaks failed to
allow specific designation to any isolated metabolites
identified in previous studies. This highlights the com-
plexity of identifying individual compounds that have
potential beneficial effects and equally ignores any
potential synergistic effects that may be seen.
Fig. 3 BME suppresses TM-induced UPR activation in LS174T colonic epithelial cells. LS174T cells pre-treated, co-treated or post-treated with
0.125% and 0.25% BME for 6 h prior to, during or after ER stress induction using tunicamycin (10 μg/mL). mRNA expression of UPR genes ATF6,
XBP1, GRP78, CHOP and PERK in LS174T cells were measured by qRT-PCR. The mRNA gene expression is relative to TM (10ug/mL in DMSO)
expression and normalized to GAPDH (n = 5) Data are shown as the mean fold change ± SEM (significance testing vs TM: *, **, ***; p < 0.05, p < 0.01
and p < 0.001 respectively)
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Therefore, large scale extraction/isolation is war-
ranted to determine metabolites responsible for the
activity seen in this study. The beneficial effects of BM
have been demonstrated in numerous pre-clinical
studies. Mice fed with a high fat diet (HFD) supple-
mented with 0.5%, 0.75% or higher concentration of
freeze-dried BME demonstrated an improvement in
their glucose, lipid and lipoprotein metabolism [4, 33].
Preliminary studies have shown that BM reduces hep-
atic ER stress markers such as GRP78 and CHOP in
HFD-fed mice [34]. BM also reduced the release of
pro-inflammatory cytokines and inhibited neuroin-
flammation in the brains of HFD-fed mice [34].
Accumulation of mis-folded protein in TM-induced
ER stress results in activation of the UPR via multiple
intracellular signalling pathways that aim to restore ER
homeostasis [23, 35, 36]. In this study, we demonstrated
that BME significantly suppressed TM-induced ER stress
in LS174T cells. This is supported by our results that
demonstrated a decrease in UPR-related gene expression
of ATF6, XBP1, GRP78, CHOP and PERK in LS174T
cells when treated with BME 0.125% (w/v) and BME
0.25% (w/v). This suggests that dietary BME could be a
potential therapeutic strategy in ameliorating ER stress
in colonic epithelial cells in order to reduce the risk of
IBD and also various ER stress-mediated human diseases
that involve protein mis-folding. Interestingly, the modu-
lation of ER stress markers appears to occur when
LS174T cells are co-treated with BME during a current
TM-induced ER stress period but also has an effect in
suppressing markers after a TM-induced ER stress
period, though to a lower degree.
This would suggest that BME would be effective in
ameliorating cellular responses in an already stressed en-
vironment. However, surprisingly, 0.25% BME had less
of an effect on cellular protein levels of GRP78 and
CHOP compared to 0.125% BME. The reason for this
effect could be due to the competing activities within
the extract are likely the cause of the absence of a clear
dose response at the level of CHOP expression, which
warrants the separation of BME to identify the active
components responsible for its multiple activities.
CHOP has been implicated as one of the most import-
ant components in the ER-stress induced apoptotic
Fig. 4 Western blot analysis of ER Stress markers in LS174T cells. a: Representative western blot. b: Cellular protein expression for GRP78 and
CHOP in LS174T cells pre-treated, co-treated or post-treated with 0.125% and 0.25% BME for 6 h prior to, during or after ER stress induction using
tunicamycin (10 ug/mL). The band densities were normalized to GAPDH band density. Data shown as means ± SEM (n = 2) (significance testing vs
TM: *, **, ***; p < 0.05, p < 0.01 and p < 0.001 respectively)
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pathways that aims to maintain tissue homeostasis [37].
Increasing evidence suggests that dysregulation of apop-
tosis is a primary mechanism in various human diseases.
Therefore, targeting CHOP could be important in
ameliorating ER stress [37]. Based on the findings of
this study, we demonstrated that BME efficiently
reduces ER stress processes involving CHOP, suggest-
ing that the potential mechanisms in which BME
ameliorates ER stress is by inhibiting the cells from
apoptosis and providing cell viability that attempts to
alleviate stress for survival (Fig. 5).
To our knowledge, this is the first study to demon-
strate the effect of BME treatment on ER stress in
colonic epithelial cells. Hence, this suggests that func-
tional foods that contain bioactive compounds can
potentially play a significant role in the protection of
cells from oxidative damage due to increase intracellular
ROS in the system as a result of ER stress [17, 38].
Conclusions
In this study, we have demonstrated that BME effectively
ameliorates ER stress in colonic epithelial cells. As ER
stress and oxidative stress have been implicated in the
pathogenesis of various diseases including IBD and
based on these findings in this study, BME should be
considered as a potential functional food in improving
intestinal health by ameliorating ER stress and oxidative
stress in IBD.
Further studies are warranted to investigate the active
components of BME involved in ameliorating ER- and
oxidative- stress in colonic epithelial cells, and to
examine the effects of bioactive components in human
colon cell lines. Determining the mechanisms of action
of BME in the UPR pathways could be another interest-
ing area to work on. Further in vivo studies could be
done to determine the potential therapeutic effect of BM
for the management of IBD.
Additional files
Additional file 1: Figure S1. Copper-induced oxidation curves of
human serum samples with increasing concentrations of BME w/v (▲;
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shown as mean ± SEM of n = 6. (TIF 135 kb)
Additional file 2: Table S1. Effect of increasing concentrations of BME
on copper-induced oxidation of human serum. (DOCX 12 kb)
Abbreviations
ATF6: Activating transcription factor 6; BM: Bitter melon; BME: Bitter melon
extract; CDL: Crohn’s disease; CHOP: CCAAT/-enhancer-binding protein
homologous protein; ER: Endoplasmic reticulum; ERO1: ER oxidoreductin 1;
GRP78: Glucose responsive protein 78; MUC2: Mucin 2; PERK: PRKR-like ER
kinase; PDI: Protein disulphide isomerase; TM: Tunicamycin; UPR: Unfolded
protein response; TNF: Tumor necrosis factor; XBP1: X-box binding factor 1
Funding
Not applicable.
Availability of data and materials
The materials and data of this study are available to other researchers upon
request.
Authors’ contributions
ER and KD – Conception, design, analysis and paper writing; WC, JJ, JS -
Research work & Manuscript writing; PN, DK, RE, NG and AA – Figure
preparation & Manuscript writing. All authors read and approved the final
manuscript.
Fig. 5 Proposed mechanism of BME ameliorating ER stress. BME ameliorates ER stress by supressing the expression of CHOP, a downstream
target of PERK-eIF2α-ATF4 pathway from triggering apoptosis in the cells. ATF4, Active transcription factor 4
Kunde et al. BMC Complementary and Alternative Medicine  (2017) 17:2 Page 9 of 10
Consent for publication
All authors have provided consent for publication in BMC Complementary
and Alternative Medicine.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
Not applicable.
Author details
1School of Health Sciences, University of Tasmania, Launceston 7250, TAS,
Australia. 2Department of Molecular Biosciences & Bioengineering, University
of Hawaii, Honolulu, HI, USA. 3School of Physical Sciences, University of
Tasmania, Hobart 7000, TAS, Australia. 4School of Medicine, University of
Tasmania, Hobart 7000, TAS, Australia. 5School of Health Sciences, University
of Tasmania, Locked Bag 1322, Launceston, TAS 7250, Australia.
Received: 12 July 2016 Accepted: 16 December 2016
References
1. Anant S. Methanolic extracts of bitter melon inhibit colon cancer stem cells
by affecting energy homeostasis and autophagy. Evid Based Complement
Altern Med. 2013;2013.
2. Kobori M, Nakayama H, Fukushima K, Ohnishi-Kameyama M, Ono H,
Fukushima T, Akimoto Y, Masumoto S, Yukizaki C, Hoshi Y. Bitter gourd
suppresses lipopolysaccharide-induced inflammatory responses. J Agric
Food Chem. 2008;56(11):4004–11.
3. Nerurkar P, Ray RB. Bitter melon: antagonist to cancer. Pharm Res. 2010;
27(6):1049–53.
4. Nerurkar PV, Pearson L, Efird JT, Adeli K, Theriault AG, Nerurkar VR. Microsomal
Triglyceride Transfer Protein Gene Expression and ApoB Secretion Are Inhibited
by Bitter Melon in HepG2 Cells. J Nutr. 2005;135(4):702–6.
5. Dandawate PR, Subramaniam D, Padhye SB, Anant S. Bitter melon: a
panacea for inflammation and cancer. Chin J Nat Med. 2016;14(2):81–100.
6. Horax R, Hettiarachchy N, Islam S. Total phenolic contents and phenolic
acid constituents in 4 varieties of bitter melons (Momordica charantia) and
antioxidant activities of their 401 extracts. J Food Sci. 2005;70(4):C275–80.
7. Lii C-K, Chen H-W, Yun W-T, Liu K-L. Suppressive effects of wild bitter gourd
(Momordica charantia Linn. var. abbreviata ser.) fruit extracts on
inflammatory responses in RAW 264.7 macrophages. J Ethnopharmacol.
2009;122(2):227–33.
8. Huang H-L, Hong Y-W, Wong Y-H, Chen Y-N, Chyuan J-H, Huang C-J, Chao
P-M. Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy
and down regulates lipogenic gene expression in adipose tissue of diet-
induced obese rats. Brit J Nutr. 2008;99(02):230–9.
9. Kubola J, Siriamornpun S. Phenolic contents and antioxidant activities of
bitter gourd (Momordica charantia L.) leaf, stem and fruit fraction extracts in
vitro. Food Chem. 2008;110(4):881–90.
10. Omara EA, Kam A, Alqahtania A, Li KM, Razmovski-Naumovski V, Nammi S,
Chan K, Roufogalis BD, Li GQ. Herbal medicines and nutraceuticals for
diabetic vascular complications: mechanisms of action and bioactive
phytochemicals. Curr Pharm Des. 2010;16(34):3776–414. 3807.
11. Wu S-J, Ng L-T. Antioxidant and free radical scavenging activities of wild
bitter melon (Momordica charantia Linn. var. abbreviata Ser.) in Taiwan.
LWT-Food Sci Technol. 2008;41(2):323–30.
12. Nerurkar PV, Johns LM, Buesa LM, Kipyakwai G, Volper E, Sato R, Shah P,
Feher D, Williams PG, Nerurkar VR. Momordica charantia (bitter melon)
attenuates high-fat diet-associated oxidative stress and neuroinflammation.
J Neuroinflammation. 2011;8:64.
13. Das I, Png CW, Oancea I, Hasnain SZ, Lourie R, Proctor M, Eri RD, Sheng Y,
Crane DI, Florin TH. Glucocorticoids alleviate intestinal ER stress by
enhancing protein folding and degradation of misfolded proteins. J Exp
Med. 2013;210(6):1201–16.
14. Hanauer SB. Inflammatory bowel disease: Epidemiology, pathogenesis, and
therapeutic opportunities. Inflamm Bowel Dis. 2006;12(5):S3–9.
15. Kaser A, Blumberg R. Endoplasmic reticulum stress and intestinal
inflammation. Mucosal Immunol. 2009;3(1):11–6.
16. Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, Thornton DJ,
Png CW, Crockford TL, Cornall RJ. Aberrant mucin assembly in mice causes
endoplasmic reticulum stress and spontaneous inflammation resembling
ulcerative colitis. PLoS Med. 2008;5(3):e54.
17. Damiani CR, Benetton CA, Stoffel C, Bardini KC, Cardoso VH, Di Giunta G,
Pinho RA, Dal‐Pizzol F, Streck EL. Oxidative stress and metabolism in animal
model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol.
2007;22(11):1846–51.
18. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of
inflammatory bowel disease: an epiphenomenon or the cause? Digest Dis
Sci. 2007;52(9):2015–21.
19. Alfadda AA, Sallam RM. Reactive oxygen species in health and disease.
J Biomed Biotechnol. 2012;2012:936486.
20. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress:
a vicious cycle or a double-edged sword? Antioxid Redox Signal. 2007;9(12):
2277–94.
21. Deuring JJ, Peppelenbosch M, Kuipers E, vander CJ W, de Haar C. Impeded
protein folding and function in active inflammatory bowel disease. Biochem
Soc T. 2011;39(4):1107.
22. Kucharzik T, Maaser C, Lügering A, Kagnoff M, Mayer L, Targan S, Domschke
W. Recent understanding of IBD pathogenesis: Implications for future
therapies. Inflamm Bowel Dis. 2006;12(11):1068–83.
23. McGuckin MA, Eri RD, Das I, Lourie R, Florin TH. ER stress and the unfolded
protein response in intestinal inflammation. American journal of physiology
Gastrointestinal and liver physiology. 2010;298(6):G820–832.
24. Lih-Brody L, Collier KP, Reddy GM, Cerchia R, Kahn E, Weissman GS, Katz S,
McKinley MJ, Fisher SE, Mullin GE. Increased oxidative stress and decreased
antioxidant defenses in mucosa of inflammatory bowel disease. Digest Dis
Sci. 1996;41(10):2078–86.
25. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for
prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):
1397–421.
26. Hao X, Yao A, Gong J, Zhu W, Li N, Li J. Berberine ameliorates pro-
inflammatory cytokine-induced endoplasmic reticulum stress in human
intestinal epithelial cells in vitro. Inflammation. 2012;35(3):841–9.
27. Just J, Deans BJ, Olivier WJ, Paull B, Bissember AC, Smith JA. New method
for the rapid extraction of natural products: efficient isolation of shikimic
acid from star anise. Org Lett. 2015;17(10):2428–30.
28. Just J, Jordan TB, Paull B, Bissember AC, Smith JA. Practical isolation of
polygodial from Tasmannia lanceolata: a viable scaffold for synthesis. Org
Biomol Chem. 2015;13(46):11200–7.
29. Schnitzer E, Pinchuk I, Bor A, Fainaru M, Samuni AM, Lichtenberg D. Lipid
oxidation in unfractionated serum and plasma. Chem Phys Lipids. 1998;
92(2):151–70.
30. Ahuja KD, Kunde DA, Ball MJ, Geraghty DP. Effects of capsaicin,
dihydrocapsaicin, and curcumin on copper-induced oxidation of human
serum lipids. J Agric Food Chem. 2006;54(17):6436–9.
31. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST©)
for group-wise comparison and statistical analysis of relative expression
results in real-time PCR. Nucleic Acids Res. 2002;30(9):e36.
32. Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, Tang CP, Chen T, Weiss
HC, Gesing ER, Rowland A, et al. Antidiabetic activities of triterpenoids
isolated from bitter melon associated with activation of the AMPK pathway.
Chem Biol. 2008;15(3):263–73.
33. Chen Q, Chan LL, Li ET. Bitter melon (Momordica charantia) reduces
adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed
a high fat diet. J Nutr. 2003;133(4):1088–93.
34. Nerurkar PV. 2nd World Congress on. Diabetes. 2011;6(8).
35. Bogaert S, De Vos M, Olievier K, Peeters H, Elewaut D, Lambrecht B, Pouliot
P, Laukens D. Involvement of endoplasmic reticulum stress in inflammatory
bowel disease: a different implication for colonic and ileal disease? PLoS
One. 2011;6(10):e25589.
36. Rasheva V, Domingos P. Cellular responses to endoplasmic reticulum stress
and apoptosis. Apoptosis. 2009;14(8):996–1007.
37. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum
stress. Cell Death Differ. 2003;11(4):381–9.
38. Bhardwaj P. Oxidative stress and antioxidants in gastrointestinal diseases.
Trop Gastroenterol. 2010;29(3):129–35.
Kunde et al. BMC Complementary and Alternative Medicine  (2017) 17:2 Page 10 of 10
